An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Registration Number
- NCT01860144
- Lead Sponsor
- Peking University
- Brief Summary
This observational, multicenter, prospective study will evaluate the use of bevacizumab in real clinical practice in chinese patients with metastatic colorectal cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
- histologically confirmed metastatic colorectal cancer patients Having initiated treatment with bevacizumab
Read More
Exclusion Criteria
- non-metastatic colorectal cancer patients not recieved bevacizumab
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description bevacizumab Bevacizumab Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab
- Primary Outcome Measures
Name Time Method Objective response rate 6 weeks To evaluate the treatment response of bevacizumab in Chinese patients with mCRC in real clinical practice
- Secondary Outcome Measures
Name Time Method overall survival 3 months OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost
progression free survival 6 weeks the follow-up visit of PFS will be performed every 6 weeks
resection rate 1 month resection rate of tumor after chemotherapy plus bevacizumab
Proportion of patients with bevacizumab treatment discontinuation 3 weeks Proportion of patients with bevacizumab treatment discontinuation due to bevacizumab-related adverse events
Trial Locations
- Locations (1)
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China